Freshworks Inc vs Immunovant Inc. Common Stock — how do they compare? Freshworks Inc trades at $13.74 (market cap $3.56B), while Immunovant Inc. Common Stock trades at $30.18 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Immunovant Inc. Common Stock for 0 Days on average.
| FRSH | IMVT | |
|---|---|---|
Market Cap | $3.56B | $6.25B |
Volume | 9,066,454 | 1,755,411 |
Sector | Technology | Health |
52-Week High | $13.92 | $44.96 |
52-Week Low | $6.88 | $17.03 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $2.93B | $5.35B |
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.60, down 1.16% on the day, with a bullish technical outlook from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with EPS of $0.17 versus $0.13 expected, and achieved its first quarter of GAAP profitability. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience portfolio and AI adoption.
The investment outlook is positive, driven by sustained revenue growth, improving profitability, and a favorable analyst consensus with a $14.60 price target. Key risks include high valuation multiples like a 43.89 EV/EBITDA and competitive pressures in the SaaS sector. The stock presents an opportunity for rerating if profitability trends continue.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →